View in EDS HTML Full Text PDF Full Text

Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.

Saved in:
Bibliographic Details
Title: Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
Authors: Matsumoto T; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan. makoharutaro2015@gmail.com.; Cancer Treatment Center, Kansai Medical University, 2‑3‑1, Hirakatashinmachi, Hirakata, Osaka, 573‑1191, Japan. makoharutaro2015@gmail.com., Ikoma T; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan., Yamamura S; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan., Miura K; Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan., Tsuduki T; Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan., Watanabe T; Department of Surgery, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan., Nagai H; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan., Takatani M; Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan., Yasui H; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.
Source: Scientific reports [Sci Rep] 2023 Jul 24; Vol. 13 (1), pp. 11935. Date of Electronic Publication: 2023 Jul 24.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37488181
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Matsumoto+T%22">Matsumoto T</searchLink>; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan. makoharutaro2015@gmail.com.; Cancer Treatment Center, Kansai Medical University, 2‑3‑1, Hirakatashinmachi, Hirakata, Osaka, 573‑1191, Japan. makoharutaro2015@gmail.com.<br /><searchLink fieldCode="AU" term="%22Ikoma+T%22">Ikoma T</searchLink>; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.<br /><searchLink fieldCode="AU" term="%22Yamamura+S%22">Yamamura S</searchLink>; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.<br /><searchLink fieldCode="AU" term="%22Miura+K%22">Miura K</searchLink>; Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.<br /><searchLink fieldCode="AU" term="%22Tsuduki+T%22">Tsuduki T</searchLink>; Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.<br /><searchLink fieldCode="AU" term="%22Watanabe+T%22">Watanabe T</searchLink>; Department of Surgery, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.<br /><searchLink fieldCode="AU" term="%22Nagai+H%22">Nagai H</searchLink>; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.<br /><searchLink fieldCode="AU" term="%22Takatani+M%22">Takatani M</searchLink>; Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.<br /><searchLink fieldCode="AU" term="%22Yasui+H%22">Yasui H</searchLink>; Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101563288%22">Scientific reports</searchLink> [Sci Rep] 2023 Jul 24; Vol. 13 (1), pp. 11935. <i>Date of Electronic Publication: </i>2023 Jul 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Published Erratum
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101563288 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2045-2322 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220452322%22">20452322 </searchLink><i>NLM ISO Abbreviation: </i>Sci Rep <i>Subsets: </i>MEDLINE; PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37488181
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41598-023-39009-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 11935
    Titles:
      – TitleFull: Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Matsumoto T
      – PersonEntity:
          Name:
            NameFull: Ikoma T
      – PersonEntity:
          Name:
            NameFull: Yamamura S
      – PersonEntity:
          Name:
            NameFull: Miura K
      – PersonEntity:
          Name:
            NameFull: Tsuduki T
      – PersonEntity:
          Name:
            NameFull: Watanabe T
      – PersonEntity:
          Name:
            NameFull: Nagai H
      – PersonEntity:
          Name:
            NameFull: Takatani M
      – PersonEntity:
          Name:
            NameFull: Yasui H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 07
              Text: 2023 Jul 24
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2045-2322
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Scientific reports
              Type: main
ResultId 1